Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
- Conditions
- MonkeypoxHIV Coinfection
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 2000
- Registration Number
- NCT05965427
- Locations
- 🇫🇷
Hôpital Bichat Claude Bernard, Paris, France
🇫🇷Hôpital Pitié-Salpêtrière, Paris, France
🇵🇱Euroguidelines, Warsaw, Poland
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
- Conditions
- COVID-19Coronavirus InfectionSARS-CoV2 Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 28
- Registration Number
- NCT05593770
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
🇧🇷Hospital Federal dos Servidores do Estado, Rio De Janeiro, Brazil
🇧🇷Instituto Nacional de Infectologia Evandro Chagas, Rio De Janeiro, Brazil
HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
- Conditions
- HIV-1-infectionCOVID-19
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 2598
- Registration Number
- NCT05481216
- Locations
- 🇧🇪
CHU Saint Pierre, Brussels, Belgium
🇫🇷Hôpital Européen Marseille, Marseille, France
🇫🇷Hôpital Saint Louis, Paris, France
A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
- Conditions
- HIV I Infection
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 399
- Registration Number
- NCT05421806
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
🇫🇷Hopital Universitaire Pitie-Salpetriere, Paris, France
🇫🇷St Louis Hospital, Paris, France
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 140
- Registration Number
- NCT05349838
- Locations
- 🇧🇪
Institute of Tropical Medecine, Antwerp, Belgium
🇧🇪St Pierre University Hospital, Brussels, Belgium
🇫🇷CHU Hotel Dieu, Nantes, France
- Prev
- 1
- 2
- Next